Navigation

Synergistic Anticancer Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models

 In

Leider ist der Eintrag nur auf Britisches Englisch und Amerikanisches Englisch verfügbar. Der Inhalt wird in der Standard-Sprache dieser Website angezeigt. Sie können einen Link anklicken, um zu einer anderen verfügbaren Sprache zu wechseln.

Publication: Synergistic Anticancer Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models

Authors: Yun, Hyeok Jun, Kim, Hee Jun Kim, Jungmin Kim, Sang Yong Chang, Hang-Seok Park, Cheong Soo Chang, Ho-Jin Park, Ki Cheong

International Journal of Molecular Sciences

Abstract: Anaplastic thyroid cancer (ATC) is an undifferentiated and advanced form of thyroid cancer, accompanied with a high ratio of epigenetic adjustment, which occurs more than genetic mutations. In this study, we aimed to evaluate the synergistic anticancer effect (in vitro and in vivo) of the new combination of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA) and sorafenib with radiation therapy in pre-clinical models of ATC. The ATC cell lines, YUMC-A1 and YUMC-A2, were isolated from the current patients who were treated with HNHA and sorafenib, either as monotherapy or combination therapy. Synergistic anticancer effect of the combination therapy on the intracellular signaling pathways and cell cycle was assessed via flow cytometry and immunoblot analysis. To examine tumor shrinkage activity in vivo, an ATC cell line-derived mouse xenograft model was used. Results showed that the combination therapy of HNHA and sorafenib with radiation promoted tumor suppression via caspase cleavage and cell cycle arrest in patient-derived ATC. In addition, the combination therapy of HNHA and sorafenib with radiation was more effective against ATC than therapy with HNHA or sorafenib with radiation. Thus, the combination of HNHA and sorafenib with radiation may be used as a novel curative approach for the treatment of ATC.

Conclusion: Synergistic anticancer activity of the HNHA, sorafenib, and radiation therapy was more effective than treatment with HNHA or sorafenib alone with radiation in patient-derived ATC. These findings can be useful to design future rational clinical studies in patient with ATC to develop effective therapies.

See the full study

Please fill out your details below to download our brochures. Your only need to do once to unlock access.
Send